Opportunistic Invasive Infection by Group A Streptococcus During Anti-Interleukin-6 Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32808035.
- Also identified by DOI 10.1093/infdis/jiaa511 and PMC identifier 8030709.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Invasive group A Streptococcus (GAS) in immunocompetent individuals is largely linked to hypervirulent strains. Congenital immunodeficiencies and those acquired from chronic disease or immunosuppressant drugs also increase risk of severe illness. We recovered GAS from the blood of a patient receiving a biologic inhibitor of interleukin 6 (IL-6). Growth of this serotype M4 isolate in human blood or a murine bacteremia model was promoted by interleukin 1 or IL-6 inhibition. Hyperinvasive M1T1 GAS was unaffected by IL-6 in both models. These findings based on a natural experiment introduce IL-6 signaling deficiencies as a risk factor for invasive GAS.
Medical subject headings
- Immunotherapy
- Opportunistic Infections
- Streptococcal Infections
- Interleukin-6 Inhibitors